Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, and that is more or less 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the earliest quarter of 2021.
The analysts price targets range from a high of hundred one dolars to a low of sixty one dolars.
From the latest earnings report of its, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is actually $99.57 billion.
Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management strategies. The Long or retail Term Care segment includes selling of prescription drugs as well as assortment of general merchandise.
The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products as well as related services, including medical, pharmacy, dental, behavioural health, medical management abilities. The Corporate segment involves in offering administrative services as well as management. The company was developed by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.